Interestingly, emerging data are demonstrating the feasibility of detecting EGFR mutations in ctDNA from urine samples, potentially providing a completely non-invasive alternative sample type in the absence of the preferred tumor tissue [86–88]. This evidence concerns the gene EGFR and neoplasm.